Nisa Investment Advisors LLC lowered its position in shares of ICU Medical, Incorporated (NASDAQ:ICUI) by 6.6% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 11,493 shares of the medical instruments supplier’s stock after selling 807 shares during the period. Nisa Investment Advisors LLC owned 0.06% of ICU Medical worth $2,118,000 as of its most recent filing with the SEC.
Other institutional investors have also recently added to or reduced their stakes in the company. Synovus Financial Corp grew its position in shares of ICU Medical by 1,272.7% during the first quarter. Synovus Financial Corp now owns 151 shares of the medical instruments supplier’s stock worth $30,000 after acquiring an additional 140 shares during the last quarter. Arden Trust Co acquired a new stake in ICU Medical in the first quarter worth about $64,000. Signaturefd LLC lifted its holdings in ICU Medical by 38.5% in the first quarter. Signaturefd LLC now owns 360 shares of the medical instruments supplier’s stock worth $73,000 after purchasing an additional 100 shares during the period. Dupont Capital Management Corp acquired a new stake in ICU Medical in the first quarter worth about $93,000. Finally, Exane Derivatives lifted its holdings in ICU Medical by 5,533.3% in the first quarter. Exane Derivatives now owns 507 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 498 shares during the period. Institutional investors and hedge funds own 93.03% of the company’s stock.
Several equities research analysts recently weighed in on ICUI shares. BidaskClub raised shares of ICU Medical from a “sell” rating to a “hold” rating in a report on Saturday, July 18th. Raymond James upped their price objective on shares of ICU Medical from $215.00 to $228.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. ValuEngine downgraded shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Monday, April 27th. KeyCorp reduced their price objective on shares of ICU Medical from $206.00 to $199.00 and set an “overweight” rating for the company in a report on Wednesday, May 13th. Finally, Zacks Investment Research raised shares of ICU Medical from a “sell” rating to a “hold” rating in a report on Wednesday, July 15th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $211.67.
In other ICU Medical news, Director George A. Lopez sold 16,551 shares of the business’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $197.37, for a total transaction of $3,266,670.87. Following the sale, the director now owns 346,202 shares in the company, valued at approximately $68,329,888.74. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Vivek Jain sold 15,000 shares of the business’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $203.87, for a total value of $3,058,050.00. Following the sale, the chief executive officer now owns 81,211 shares in the company, valued at approximately $16,556,486.57. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 45,969 shares of company stock worth $9,056,253. Corporate insiders own 10.90% of the company’s stock.
Shares of NASDAQ ICUI opened at $183.73 on Friday. ICU Medical, Incorporated has a twelve month low of $148.89 and a twelve month high of $259.72. The company has a market capitalization of $3.83 billion, a price-to-earnings ratio of 27.92 and a beta of 0.54. The firm has a 50-day moving average of $183.69 and a two-hundred day moving average of $194.88.
ICU Medical (NASDAQ:ICUI) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.81 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.63 by $0.18. The firm had revenue of $328.61 million for the quarter, compared to the consensus estimate of $302.97 million. ICU Medical had a return on equity of 10.45% and a net margin of 6.87%. The business’s revenue for the quarter was down .7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.58 EPS. On average, sell-side analysts anticipate that ICU Medical, Incorporated will post 5.32 EPS for the current year.
ICU Medical Profile
ICU Medical, Inc develops, manufactures, and sells medical devices used in vascular therapy, critical care, and oncology applications worldwide. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patient's vein.
Featured Story: Penny Stocks, Risk and Reward Factors
Want to see what other hedge funds are holding ICUI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ICU Medical, Incorporated (NASDAQ:ICUI).
Receive News & Ratings for ICU Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ICU Medical and related companies with MarketBeat.com's FREE daily email newsletter.